New Phase 2 Data Show Treatment With TREMFYA® (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...